| BLADÉ, J., P. SONNEVELD, JF. SAN MIGUEL, HJ. SUTHERLAND, Roman HÁJEK, A NAGLER, A SPENCER, T ROBAK, MT CIBEIRA, SH ZHUANG, JL HAROUSSEAU a RZ ORLOWSKI. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment. Clinical lymphoma & myeloma. Dallas, United States: Cancer Information Group, 2008, roč. 8, č. 6, s. 352-355. ISSN 1557-9190. |
Další formáty:
BibTeX
LaTeX
RIS
@article{817650,
author = {Bladé, J. and Sonneveld, P. and San Miguel, JF. and Sutherland, HJ. and Hájek, Roman and Nagler, A and Spencer, A and Robak, T and Cibeira, MT and Zhuang, SH and Harousseau, JL and Orlowski, RZ},
article_location = {Dallas, United States},
article_number = {6},
keywords = {doxorubicin;bortezomib},
language = {eng},
issn = {1557-9190},
journal = {Clinical lymphoma & myeloma},
title = {Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment.},
volume = {8},
year = {2008}
}
TY - JOUR
ID - 817650
AU - Bladé, J. - Sonneveld, P. - San Miguel, JF. - Sutherland, HJ. - Hájek, Roman - Nagler, A - Spencer, A - Robak, T - Cibeira, MT - Zhuang, SH - Harousseau, JL - Orlowski, RZ
PY - 2008
TI - Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment.
JF - Clinical lymphoma & myeloma
VL - 8
IS - 6
SP - 352-355
EP - 352-355
PB - Cancer Information Group
SN - 15579190
KW - doxorubicin;bortezomib
N2 - A retrospective analysis was undertaken of patients (n = 193) with renal insufficiency (creatinine clearance [CrCl] < 60 mL/min) from a phase III trial comparing bortezomib +/- pegylated liposomal doxorubicin (PLD) in relapsed/refractory myeloma (n = 646). The response rate (49% vs. 42%) and median time to disease progression (331 days vs. 199 days) were comparable or slightly better for patients with renal insufficiency treated with PLD/bortezomib compared with patients treated with bortezomib alone. There was a steady, clinically meaningful improvement in renal function for patients with renal insufficiency in both treatment arms. However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and > or = 60 mL/min, respectively).
ER -
BLADÉ, J., P. SONNEVELD, JF. SAN MIGUEL, HJ. SUTHERLAND, Roman HÁJEK, A NAGLER, A SPENCER, T ROBAK, MT CIBEIRA, SH ZHUANG, JL HAROUSSEAU a RZ ORLOWSKI. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment. \textit{Clinical lymphoma \&{} myeloma}. Dallas, United States: Cancer Information Group, 2008, roč.~8, č.~6, s.~352-355. ISSN~1557-9190.
|
